The latest price target for Artiva Biotherapeutics (NASDAQ:ARTV) was reported by HC Wainwright & Co. on December 30, 2024. The analyst firm set a price target for $20.00 expecting ARTV to rise to within 12 months (a possible 100.60% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Artiva Biotherapeutics (NASDAQ:ARTV) was provided by HC Wainwright & Co., and Artiva Biotherapeutics initiated their buy rating.

There is no last upgrade for Artiva Biotherapeutics

There is no last downgrade for Artiva Biotherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Artiva Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Artiva Biotherapeutics was filed on December 30, 2024 so you should expect the next rating to be made available sometime around December 30, 2025.

While ratings are subjective and will change, the latest Artiva Biotherapeutics (ARTV) rating was a initiated with a price target of $0.00 to $20.00. The current price Artiva Biotherapeutics (ARTV) is trading at is $9.97, which is within the analyst’s predicted range.